The Journey of Apixaban

Apixaban is rapidly absorbed from the gut with oral bioavailability
of approximately 50% after dosing at 10 mg or less; at higher doses, bioavailability decreases
slightly. Peak plasma concentrations are achieved within 3-4 hours. Unlike rivaroxaban, apixaban
does not require food for adequate absorption — it can be taken with or without food at all doses.
The drug is available as 2.5 mg and 5 mg tablets; for patients who cannot swallow tablets, the
crushed tablet can be suspended in water or 5% dextrose, or mixed with applesauce, and administered
via nasogastric tube. Apixaban does not interact significantly with gastric acid-reducing agents
(H2-blockers, proton pump inhibitors), making it suitable for patients requiring acid suppression.
For VTE treatment, a higher initial dose of 10 mg twice daily for 7 days is used, then reduced
to 5 mg twice daily, exploiting the dose-dependent anticoagulation.

Apixaban distributes moderately into tissues with a volume of
distribution of approximately 21 L. Plasma protein binding is high at approximately 87%, primarily
to albumin. The modest Vd combined with high protein binding indicates limited extravascular
distribution beyond plasma and interstitial fluid. Apixaban does not significantly penetrate the
blood-brain barrier. The drug inhibits Factor Xa in the prothrombinase complex (membrane-anchored
FXa in complex with Factor Va on activated platelet surfaces) as well as free Factor Xa in
circulation — a mechanistic advantage proposed to reflect superior thrombus prevention compared
to indirect Xa inhibitors (low-molecular-weight heparins) that cannot access clot-bound FXa.
Andexanet alfa, a modified Factor Xa decoy, rapidly reverses apixaban anticoagulation in bleeding
emergencies.

Apixaban selectively and directly inhibits Factor Xa (FXa), the
serine protease at the convergence of the intrinsic and extrinsic coagulation pathways, without
requiring antithrombin as a cofactor (unlike heparins). Apixaban binds the active site of FXa
with high selectivity (>30,000-fold over thrombin, trypsin, and other serine proteases) and potency
(Ki ~0.08 nM — approximately 5-fold more potent than rivaroxaban's Ki of ~0.4 nM). Inhibition
is competitive, reversible, and concentration-dependent. The pyrazolopyrimidine scaffold forms
multiple hydrogen bonds and hydrophobic contacts within the FXa active-site S1 and S4 pockets.
By preventing FXa from cleaving prothrombin to thrombin, apixaban blocks fibrin clot formation
and thrombin-mediated platelet activation (PAR-1 and PAR-4). Apixaban does not inhibit platelet
aggregation directly and does not significantly affect bleeding time, distinguishing it from
antiplatelet agents.

Apixaban is metabolized primarily by CYP3A4 (major pathway,
approximately 25% of total clearance) and CYP3A5, with minor contributions from CYP1A2, CYP2J2.
Sulfation by SULT1A1 and glucuronidation contribute to overall elimination. Approximately 25% of
the total dose undergoes CYP-mediated metabolism. The primary metabolite (O-demethyl apixaban)
is formed by CYP3A4 and has negligible pharmacological activity. P-glycoprotein (P-gp/ABCB1)
and BCRP (ABCG2) are important efflux transporters at the gut wall and kidney, limiting oral
bioavailability and renal secretion. Combined strong inhibitors of CYP3A4 and P-gp (ketoconazole,
itraconazole, ritonavir) increase apixaban AUC by approximately 2-fold, requiring dose reduction
(2.5 mg twice daily). Combined strong inducers (rifampicin, carbamazepine, phenytoin) reduce
apixaban AUC by approximately 54%, risking thromboembolism.

Apixaban is excreted via multiple routes: approximately 27% is
excreted unchanged in urine (via glomerular filtration and active secretion by P-gp and BCRP),
approximately 56% in feces (as unchanged drug and metabolites via biliary secretion and direct
intestinal excretion), and approximately 15% as metabolites in urine. The elimination half-life
is approximately 12 hours, supporting twice-daily dosing. Renal clearance of unchanged apixaban
is approximately 27% of total clearance — less than rivaroxaban (36%) — meaning that dose adjustment
in renal impairment is less urgent. Dose reduction to 2.5 mg twice daily in AF patients is required
when 2 of 3 criteria are met (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL). Andexanet alfa
reverses apixaban anticoagulation within minutes by acting as a high-affinity decoy FXa molecule.

Apixaban (Eliquis) demonstrated superior efficacy over warfarin for
stroke prevention in atrial fibrillation in ARISTOTLE (21% reduction in stroke or systemic embolism)
along with significantly less major bleeding and intracranial hemorrhage. For VTE treatment, the
AMPLIFY trial showed non-inferiority to standard therapy with significantly less major bleeding.
Compared to rivaroxaban, apixaban requires twice-daily dosing but has more balanced renal-hepatic
elimination. Unlike rivaroxaban's 20 mg evening dose requirement, apixaban has no food requirement
and can be dosed any time. GI bleeding is lower with apixaban than rivaroxaban among the NOACs.
Reversal with andexanet alfa is more expensive than four-factor PCC; idarucizumab (for dabigatran)
has no effect on FXa inhibitors.